Metformin synergically sensitized AML cells to Ara-C via inhibiting the mTORC1/p70S6K pathway, exhibiting significantly synergistic anti-tumor effects (Visnjic et al., 2019; Yuan et al., 2020). Here, RPS6KB1 is linked to neoplasm.